Bromide

Bromide

SCHEMBL616105

C1=CC([Zr+2]2(C3C=Cc4ccccc43)CC2)c2ccccc21.[Br-].[Br-]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.33
CHRM1 known ✓ P11229 1/20 0.33
CHRM3 known ✓ P20309 1/20 0.33
HTR2A P28223 2/20 0.39
HTR6 P50406 1/20 0.35
CYP2D6 P10635 3/20 0.34
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
NFKB1 P19838 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
THPO P40225 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL648408 0.96 HTR2A (0.35) HTR2AHTR6CYP2D6
Hydrochloric Acid SCHEMBL151866 0.96 HTR2A (0.35) HTR2AHTR6CYP2D6
SCHEMBL5839790 0.96 HTR2A (0.35) HTR2AHTR6CYP2D6
Fluoride Ion SCHEMBL1130929 0.96 HTR2A (0.35) HTR2AHTR6CYP2D6
Hydrochloric Acid SCHEMBL7190324 0.94 HTR2A (0.34) HTR2AHTR6CYP2D6
SCHEMBL6357318 0.92 HTR2A (0.33) HTR2AHTR6CYP2D6KDM4ELMNA
SCHEMBL7110550 0.91 HTR6 (0.33) HTR2AHTR6CYP2D6KDM4ELMNA
Hydrochloric Acid SCHEMBL8017987 0.91 HTR6 (0.33) HTR2AHTR6CYP2D6KDM4ELMNA
Hydrochloric Acid SCHEMBL7518120 0.89 HTR6 (0.32) HTR2AHTR6
Hydrochloric Acid SCHEMBL647120 0.89 HTR6 (0.33) HTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0294942-B2 Solid catalyst for polymerizing an olefin MITSUI CHEMICALS INC (JP) 2002-05-08 EP claimed
EP-0294942-B1 Solid catalyst for polymerizing an olefin MITSUI PETROCHEMICAL IND (JP) 1994-07-13 EP claimed
US-20230137384-A1 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY URIGEN PHARMACEUTICALS, INC. 2023-05-04 US disclosed
US-20210283172-A1 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY URIGEN PHARMACEUTICALS, INC. 2021-09-16 US disclosed
US-10870715-B2 Solid polyaluminoxane composition, olefin polymerization catalyst, olefin polymer production method and solid polyaluminoxane composition production method MITSUI CHEMICALS, INC. (JP) 2020-12-22 US disclosed
EP-3609483-A1 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY Urigen Pharmaceuticals, Inc. (US) 2020-02-19 EP disclosed
EP-3312200-B1 SOLID POLYALUMINOXANE COMPOSITION, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMER PRODUCTION METHOD AND SOLID POLYALUMINOXANE COMPOSITION PRODUCTION METHOD MITSUI CHEMICALS INC (JP) 2019-06-19 EP disclosed
WO-2018191412-A9 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY URIGEN PHARMACEUTICALS, INC. (US) 2019-05-31 WO disclosed
US-10150823-B2 Solid polyaluminoxane composition, olefin polymerization catalyst, olefin polymer production method and solid polyaluminoxane composition production method MITSUI CHEMICALS, INC. (JP) 2018-12-11 US disclosed
WO-2018191412-A1 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY URIGEN PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed
EP-3312200-A1 SOLID POLYALUMINOXANE COMPOSITION, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMER PRODUCTION METHOD AND SOLID POLYALUMINOXANE COMPOSITION PRODUCTION METHOD Mitsui Chemicals, Inc. (JP) 2018-04-25 EP disclosed
EP-0327649-A1 CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR ITS PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1989-08-16 EP disclosed
EP-0324856-A1 PROCESS FOR POLYMERIZING OLEFIN MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1989-07-26 EP disclosed
EP-0314797-A1 OLEFIN POLYMERIZATION CATALYST AND PROCESS FOR POLYMERIZING OLEFIN MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1989-05-10 EP disclosed
EP-0295312-A1 SOLID CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR ITS PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-12-21 EP disclosed
EP-0294942-A1 Solid catalyst for polymerizing an olefin MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-12-14 EP disclosed
EP-0287666-A1 PROCESS FOR POLYMERIZING OLEFINS Mitsui Chemicals, Inc. (JP) 1988-10-26 EP disclosed
EP-0283164-A2 Cyclo-olefinic random copolymer, olefinic random copolymer, and process for producing cyclo-olefinic random copolymers MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-09-21 EP disclosed
EP-0279863-A1 CATALYST FOR POLYMERIZING ALPHA-OLEFIN AND POLYMERIZATION PROCESS MITSUI CHEMICALS, INC. (JP) 1988-08-31 EP disclosed
EP-0279586-A2 Finely divided aluminoxane, process for producing same and its use MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210283172-A1 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY OGFR, ALOX5, PTGS1 CHRM2 2397/4885CHRM1 2318/4885CHRM3 1884/4885
US-20230137384-A1 ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY OGFR, ALOX5, PTGS1 CHRM2 2397/4885CHRM1 2318/4885CHRM3 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.